Endocrinology Topic Track

Laboratorians play a key role in the diagnostic assessment of endocrine disorders, and have insights into the controversies and challenges in the field. Sessions in the Endocrinology Topic Track explore these issues in depth.

Monday

What Are Disorders of Sexual Development? 72107

This session will describe the classification, biology, and diagnosis of disorders of sexual development. This short course will provide the laboratorian with the essential knowledge required to assist clinicians in the evaluation of such complex cases.

Speaker: William Winter, MD, FCAP, FACB, DABCC, Univ. of Florida, Gainesville.

Measurement of Free Hormones in Blood: Technical and Clinical Challenges 32411
Developed in cooperation with the Endocrine Society and Clinical Societies Collaboration Committee.

Measurement and interpretation of free hormones in blood are among the most challenging problems in clinical endocrinology and clinical chemistry. The reliability of the measurement of serum free thyroid hormone has been called into question in several common clinical conditions including pregnancy and monitoring patients on thyroid hormone replacement. Interpretation of free plasma steroid measurements such as cortisol is also very challenging, and the use of salivary steroid measurements as a surrogate has been proposed. This symposia will discuss the general problem, and then focus on free thyroid hormone and free cortisol measurements.

Moderator: David Sacks, MB, ChB, FRCPath, NIH, Bethesda, MD.

Speakers: Free Hormones in the Blood – Technical Issues Influencing Clinical Interpretation, Steven Soldin, PhD, ABCC, National Institutes of Health, Bethesda, MD; Clinical Experiences With Free Thyroid Hormones, Jacquie Jonklaas, MD, PhD, Georgetown University, Washington, DC; Free Steroid Hormones, Jean-Benoit Corcuff, MD, PhD, University of Bordeaux, Pessac, France.

Obesity and Cancer 72223

About 30–35% adults in the U.S. are obese. Obesity carries a significant risk for cancer development and progression. Recent studies suggest that dysregulated hormones from adipose tissue lead to insulin resistance via secretion of pro-inflammatory cytokines and adipokines. One of the major adipokines, leptin, is known to play a central role in obesity-related cancer. Recent findings on molecular mechanisms of leptin and adiponectin will be discussed.

Moderator: Manjula Gupta, PhD, Cleveland Clinic Foundation, OH.

Speakers: Epidemiology and Proposed Mechanisms [Insulin Resistance] in Obesity and Cancer, Manjula Gupta, PhD, Cleveland Clinic Foundation, OH; Role of Leptin Signaling in Cancer Development and Progression, Ofer Reizes, PhD, Cleveland Clinic, OH.

*Brown Bag Session: The Assessment of Insulin Resistance and Selection of the Appropriate Method for the Assessment 42105 (Repeats as 52205)

Speaker: Anwar Borai King Khalid National Guard Hospital, Jeddah, Saudi Arabia.

*Brown Bag Session: Diagnosis and Monitoring of Congenital Adrenal Hyperplasia, Polycystic Ovarian Syndrome and Pubertal Abnormalities Using Mass Spectrometry 42111 (Repeats as 52211)

Speaker: Lorin Bachmann, PhD, DABCC, Virginia Commonwealth University, Richmond, VA.

*Brown Bag Session: Measurements of Total and Free Testosterone in Clinical Laboratories 42123 (Repeats as 52223)

Speaker: Jing Cao, PhD, University of Minnesota, Minneapolis, MN.

Tuesday

*Brown Bag Session: Parathyroid Hormone Assay Challenges and Harmonization Progress 43102 (Repeats as 53202)

Speaker: Asmita Hazra, MBBS, MD, AIIMS ND, Christian Medical College Vellore India, Vellore, Tamil Nadu.

*Brown Bag Session: Thyroglobulin and Anti-Thyroglobulin Autoantibodies Assays in the Management of Thyroid Cancer Patients: Which Assay Should I Offer? 43108 (Repeats as 53208)

Speaker: Alicia Algeciras-Schimnich, PhD, DABCC, Mayo Clinic, Rochester, MN.

*Brown Bag Session: Laboratory Tests Related To Calcium and Bone Metabolism 43117 (Repeats as 53217)

Speaker: Lu Song, PhD, DABCC, UCLA Medical Center, Los Angeles, CA.

Diabetic Nephropathy: Where Are We Now? 33211

This session will address key biomarkers for diabetic kidney disease (creatinine, eGFR, cystatin C, urine albumin) in the context of physiologic and laboratory limitations that influence interpretation of results, how eGFR is used to make treatment decisions, and whether the biomarkers are adequate for assessing renal function in diabetes.

Moderator: David Sacks, MB, ChB, FRCPath, NIH, Bethesda, MD.

Speakers: How Accurately Can We Measure Renal Function in Diabetes?, Greg Miller, PhD, DABCC, Virginia Commonwealth University, Richmond; Reporting eGFR From Creatinine: Progress and Lessons Learned, Andrew Narva, MD, FACP, FASN, National Kidney Disease Education Program, Bethesda, MD; Assessing Prognosis in Diabetic Kidney Disease: Are Urine Albumin and eGFR Enough?, Katherine Tuttle, University of Washington, Spokane.


*About Brown Bag sessions: These small discussion settings provide intimate exchanges between participants and experts. Expect lively conversation, dialogue, and debate, as well as Q&As. Attendance is limited to 10 participants. Advance registration and fees are required.